Undiagnosed Myeloproliferative Disease in Cases of Intra-Abdominal Thrombosis: The Utility of the JAK2 617F Mutation

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 4, 2008, Pages 472-475

  P'ng, Stephanie ^a   Carnley, Ben ^a   Baker, Ross ^a   Kontorinis, Nick ^a   Cheng, Wendy ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; JANUS KINASE 2; WARFARIN;

ABDOMINAL RADIOGRAPHY; AGED; ALLELE; ARTICLE; ASCITES; BUDD CHIARI SYNDROME; CASE REPORT; CHROMOSOME ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; ESOPHAGUS VARICES; FEMALE; GASTRIC BANDING; GASTROSCOPY; GRANULOCYTE; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; INCIDENCE; LABORATORY TEST; LEUKOCYTE COUNT; LIVER BIOPSY; MUTATION; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; PORTAL VEIN THROMBOSIS; POSTOPERATIVE CARE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCLEROTHERAPY; SPLENECTOMY; SYMPTOMATOLOGY; THROMBOCYTHEMIA;

AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERSPLENISM; JANUS KINASE 2; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; PORTAL VEIN; THROMBOCYTOSIS; VENOUS THROMBOSIS;

EID: 41149143505     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.12.046     Document Type: Article

References (17)

1. Denninger M.H., Chait Y., Casadevall N., et al. Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors. Hepatology 31 (2000) 587-591
2. Primignani M., Martinelli I., and Bucciarelli P. Risk factors for thrombophilia in extrahepatic protal vein obstruction. Hepatology 41 (2005) 603-608
3. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365 (2005) 1054-1061
4. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
5. James C., Ugo V., Le Couedic J.P., et al. Unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
6. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
7. Hammond E., Shaw K., Carnley B., et al. Quantitative determination of JAK2 V617F by TaqManan absolute measure of averaged copies per cell that reflects myeloproliferation. J Mol Diagn 9 (2007) 242-248
8. Wernig G., Mercher T., Okabe R., et al. Expression of JAK2 V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
9. Primignani M., Barosi G., Bergamaschi G., et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44 (2006) 1528-1534
10. Patel R.K., Lea N.C., Heneghan M.A., et al. Prevalence of the activation JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130 (2006) 2013-2038
11. In: Miescher P.A., Jaffe E.R., Beris P., et al. (Eds). Polycythemia vera. Semin Hematol 34 (1997) 1-80
12. In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France
13. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2 V617F Era. ASH Education Book (2006) 240-245. http://www.asheducationbook.org www.asheducationbook.org
14. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
15. Tefferi A., Lasho T.L., Schwager S.M., et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131 (2005) 320-328
16. Wolanskyj A.P., Lasho T.L., Schwager S.M., et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131 (2005) 208-213
17. Campell P., Griesshammer M., Dohner K., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107 (2006) 2098-2100